AU2019259818B2 - Oxo-substituted compound - Google Patents

Oxo-substituted compound Download PDF

Info

Publication number
AU2019259818B2
AU2019259818B2 AU2019259818A AU2019259818A AU2019259818B2 AU 2019259818 B2 AU2019259818 B2 AU 2019259818B2 AU 2019259818 A AU2019259818 A AU 2019259818A AU 2019259818 A AU2019259818 A AU 2019259818A AU 2019259818 B2 AU2019259818 B2 AU 2019259818B2
Authority
AU
Australia
Prior art keywords
oxy
azetidin
carboxylic acid
hydroxy
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019259818A
Other languages
English (en)
Other versions
AU2019259818A1 (en
Inventor
Takayuki Fukaya
Yohei Ikuma
Toshio Kanai
Sachiko Koike
Yuki Mizukami
Shingo MIZUSHIMA
Yoshihiko Noguchi
Hitoshi Suda
Toshiaki Sunazuka
Shunichiro Uesugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019259818(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharmaceuticals Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2019259818A1 publication Critical patent/AU2019259818A1/en
Assigned to THE KITASATO INSTITUTE, SUMITOMO DAINIPPON PHARMA CO., LTD. reassignment THE KITASATO INSTITUTE Amend patent request/document other than specification (104) Assignors: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTE
Assigned to THE KITASATO INSTITUTE, Sumitomo Pharma Co., Ltd. reassignment THE KITASATO INSTITUTE Amend patent request/document other than specification (104) Assignors: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTE
Application granted granted Critical
Publication of AU2019259818B2 publication Critical patent/AU2019259818B2/en
Assigned to Sumitomo Pharma Co., Ltd. reassignment Sumitomo Pharma Co., Ltd. Request for Assignment Assignors: Sumitomo Pharma Co., Ltd., THE KITASATO INSTITUTE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
AU2019259818A 2018-04-27 2019-04-26 Oxo-substituted compound Active AU2019259818B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-087761 2018-04-27
JP2018087761 2018-04-27
PCT/JP2019/018011 WO2019208797A1 (ja) 2018-04-27 2019-04-26 オキソ置換化合物

Publications (2)

Publication Number Publication Date
AU2019259818A1 AU2019259818A1 (en) 2020-11-26
AU2019259818B2 true AU2019259818B2 (en) 2023-06-01

Family

ID=68295570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019259818A Active AU2019259818B2 (en) 2018-04-27 2019-04-26 Oxo-substituted compound

Country Status (15)

Country Link
US (3) US11702431B2 (https=)
EP (1) EP3786168A4 (https=)
JP (2) JP7360132B2 (https=)
KR (1) KR102679411B1 (https=)
CN (2) CN112135830B (https=)
AU (1) AU2019259818B2 (https=)
CA (1) CA3098433A1 (https=)
EA (1) EA202092579A1 (https=)
IL (1) IL278262B2 (https=)
MX (1) MX2020011367A (https=)
PH (1) PH12020551772A1 (https=)
SG (1) SG11202010661SA (https=)
TW (1) TWI829686B (https=)
UA (1) UA129150C2 (https=)
WO (1) WO2019208797A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020138499A1 (ja) * 2018-12-28 2021-11-04 大日本住友製薬株式会社 アルキル置換化合物
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
US11476003B2 (en) * 2020-12-15 2022-10-18 Biodesix, Inc. Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findings
WO2024128238A1 (ja) 2022-12-13 2024-06-20 住友ファーマ株式会社 細菌感染症の治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073360A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2016003929A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073360A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors

Also Published As

Publication number Publication date
US20210147448A1 (en) 2021-05-20
PH12020551772A1 (en) 2021-07-12
TW201945006A (zh) 2019-12-01
KR102679411B1 (ko) 2024-07-01
TWI829686B (zh) 2024-01-21
IL278262B1 (en) 2024-12-01
KR20210005910A (ko) 2021-01-15
IL278262B2 (en) 2025-04-01
JPWO2019208797A1 (ja) 2021-05-27
EP3786168A1 (en) 2021-03-03
MX2020011367A (es) 2021-02-09
TW202421162A (zh) 2024-06-01
US20230287009A1 (en) 2023-09-14
AU2019259818A1 (en) 2020-11-26
IL278262A (en) 2020-12-31
JP7360132B2 (ja) 2023-10-12
EA202092579A1 (ru) 2021-04-01
JP2023168413A (ja) 2023-11-24
SG11202010661SA (en) 2020-11-27
CA3098433A1 (en) 2019-10-31
CN112135830A (zh) 2020-12-25
US11702431B2 (en) 2023-07-18
BR112020021631A8 (pt) 2023-02-28
US11066425B1 (en) 2021-07-20
BR112020021631A2 (pt) 2021-01-26
JP7598594B2 (ja) 2024-12-12
CN112135830B (zh) 2024-06-14
EP3786168A4 (en) 2022-03-23
WO2019208797A1 (ja) 2019-10-31
CN118638140A (zh) 2024-09-13
UA129150C2 (uk) 2025-01-29

Similar Documents

Publication Publication Date Title
US12221443B2 (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
ES2758507T3 (es) Nuevo inhibidor de B-lactamasa y método para producir el mismo
AU2019259818B2 (en) Oxo-substituted compound
AU2020371404A1 (en) Novel substituted condensed ring compound
WO2019009369A1 (ja) イミン誘導体
WO2019009370A1 (ja) アミド誘導体
JP7550421B2 (ja) オキソ置換化合物からなる医薬
EA048506B1 (ru) Оксо-замещенное соединение
TW202038941A (zh) 烷基取代化合物
TWI915735B (zh) 氧基取代化合物
BR112020021631B1 (pt) Composto oxo-substituído, agente de inibição de b-lactamase, composição farmacêutica, medicamento e usos
HK40023146A (en) Preparation of a diazabicyclooctane derivative
HK40023145A (en) Preparation of a diazabicyclooctane derivative
HK40043668A (en) Oxo-substituted compound
JP2020105148A (ja) 非アリールヘテロ環置換芳香族化合物

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD. ; THE KITASATO INSTITUTE

Owner name: THE KITASATO INSTITUTE

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD. ; THE KITASATO INSTITUTE

HB Alteration of name in register

Owner name: THE KITASATO INSTITUTE

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; THE KITASATO INSTITUTE

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; THE KITASATO INSTITUTE

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER OWNER(S): THE KITASATO INSTITUTE; SUMITOMO PHARMA CO., LTD.